{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T19:11:31Z","timestamp":1788462691956,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40263-023-01055-y","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T19:01:51Z","timestamp":1705863711000},"page":"45-54","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Treatment of Sleep, Motor and Sensory Symptoms with the Orexin Antagonist Suvorexant in Adults with Idiopathic Restless Legs Syndrome: A Randomized Double-Blind Crossover Proof-of-Concept Study"],"prefix":"10.1007","volume":"38","author":[{"given":"Diego","family":"Garcia-Borreguero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba Garcia","family":"Arag\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Moncada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Granizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Quintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,21]]},"reference":[{"issue":"8","key":"1055_CR1","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.sleep.2014.03.025","volume":"15","author":"RP Allen","year":"2014","unstructured":"Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, Zucconi M, Ferri R, Trenkwalder C, Lee HB. G. International restless legs syndrome study, restless legs syndrome\/Willis\u2013Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria\u2014history, rationale, description, and significance. Sleep Med. 2014;15(8):860\u201373.","journal-title":"Sleep Med"},{"issue":"2","key":"1055_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.sleep.2011.09.015","volume":"13","author":"D Tzonova","year":"2012","unstructured":"Tzonova D, Larrosa O, Calvo E, Granizo JJ, Williams AM, de la Llave Y, Garcia-Borreguero D. Breakthrough symptoms during the daytime in patients with restless legs syndrome (Willis\u2013Ekbom disease). Sleep Med. 2012;13(2):151\u20135.","journal-title":"Sleep Med"},{"key":"1055_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.sleep.2016.01.017","volume":"21","author":"D Garcia-Borreguero","year":"2016","unstructured":"Garcia-Borreguero D, Silber MH, Winkelman JW, Hogl B, Bainbridge J, Buchfuhrer M, Hadjigeorgiou G, Inoue Y, Manconi M, Oertel W, Ondo W, Winkelmann J, Allen RP. Guidelines for the first-line treatment of restless legs syndrome\/Willis\u2013Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 2016;21:1\u201311.","journal-title":"Sleep Med"},{"issue":"7","key":"1055_CR4","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.sleep.2013.05.016","volume":"14","author":"D Garcia-Borreguero","year":"2013","unstructured":"Garcia-Borreguero D, Kohnen R, Silber MH, Winkelman JW, Earley CJ, Hogl B, Manconi M, Montplaisir J, Inoue Y, Allen RP. The long-term treatment of restless legs syndrome\/Willis\u2013Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14(7):675\u201384.","journal-title":"Sleep Med"},{"issue":"10","key":"1055_CR5","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.sleep.2012.08.004","volume":"13","author":"MC Lipford","year":"2012","unstructured":"Lipford MC, Silber MH. Long-term use of pramipexole in the management of restless legs syndrome. Sleep Med. 2012;13(10):1280\u20135.","journal-title":"Sleep Med"},{"issue":"5","key":"1055_CR6","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.sleep.2010.11.002","volume":"12","author":"N Silver","year":"2011","unstructured":"Silver N, Allen RP, Senerth J, Earley CJ. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med. 2011;12(5):440\u20134.","journal-title":"Sleep Med"},{"issue":"10","key":"1055_CR7","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.sleep.2015.05.028","volume":"16","author":"T Mitterling","year":"2015","unstructured":"Mitterling T, Heidbreder A, Stefani A, Fritz J, Ulmer H, Poewe W, Hogl B. Natural course of restless legs syndrome\/Willis\u2013Ekbom disease: long-term observation of a large clinical cohort. Sleep Med. 2015;16(10):1252\u20138.","journal-title":"Sleep Med"},{"issue":"1","key":"1055_CR8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.sleep.2007.11.024","volume":"10","author":"C Gamaldo","year":"2009","unstructured":"Gamaldo C, Benbrook AR, Allen RP, Oguntimein O, Earley CJ. Evaluating daytime alertness in individuals with Restless Legs Syndrome (RLS) compared to sleep restricted controls. Sleep Med. 2009;10(1):134\u20138.","journal-title":"Sleep Med"},{"key":"1055_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/NSS.S138823","volume":"10","author":"DA Kalmbach","year":"2018","unstructured":"Kalmbach DA, Cuamatzi-Castelan AS, Tonnu CV, Tran KM, Anderson JR, Roth T, Drake CL. Hyperarousal and sleep reactivity in insomnia: current insights. Nat Sci Sleep. 2018;10:193\u2013201.","journal-title":"Nat Sci Sleep"},{"issue":"2","key":"1055_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1073858418791763","volume":"25","author":"S Ferre","year":"2019","unstructured":"Ferre S, Garcia-Borreguero D, Allen RP, Earley CJ. New insights into the neurobiology of restless legs syndrome. Neuroscientist. 2019;25(2):113\u201325.","journal-title":"Neuroscientist"},{"key":"1055_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.neubiorev.2014.12.005","volume":"49","author":"B Hu","year":"2015","unstructured":"Hu B, Yang N, Qiao QC, Hu ZA, Zhang J. Roles of the orexin system in central motor control. Neurosci Biobehav Rev. 2015;49:43\u201354.","journal-title":"Neurosci Biobehav Rev"},{"key":"1055_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.peptides.2013.11.014","volume":"52","author":"LG Nisembaum","year":"2014","unstructured":"Nisembaum LG, de Pedro N, Delgado MJ, Sanchez-Bretano A, Isorna E. Orexin as an input of circadian system in goldfish: effects on clock gene expression and locomotor activity rhythms. Peptides. 2014;52:29\u201337.","journal-title":"Peptides"},{"issue":"18","key":"1055_CR13","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.cub.2013.07.014","volume":"23","author":"CR Burgess","year":"2013","unstructured":"Burgess CR, Peever JH. A noradrenergic mechanism functions to couple motor behavior with arousal state. Curr Biol. 2013;23(18):1719\u201325.","journal-title":"Curr Biol"},{"issue":"5","key":"1055_CR14","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.conb.2013.04.008","volume":"23","author":"C Alexandre","year":"2013","unstructured":"Alexandre C, Andermann ML, Scammell TE. Control of arousal by the orexin neurons. Curr Opin Neurobiol. 2013;23(5):752\u20139.","journal-title":"Curr Opin Neurobiol"},{"issue":"3","key":"1055_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12264-012-1297-4","volume":"29","author":"XY Zhang","year":"2013","unstructured":"Zhang XY, Yu L, Zhuang QX, Zhu JN, Wang JJ. Central functions of the orexinergic system. Neurosci Bull. 2013;29(3):355\u201365.","journal-title":"Neurosci Bull"},{"key":"1055_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.639313","volume":"15","author":"C Concetti","year":"2021","unstructured":"Concetti C, Burdakov D. Orexin\/hypocretin and MCH neurons: cognitive and motor roles beyond arousal. Front Neurosci. 2021;15: 639313.","journal-title":"Front Neurosci"},{"issue":"4","key":"1055_CR17","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1212\/WNL.59.4.639","volume":"59","author":"RP Allen","year":"2002","unstructured":"Allen RP, Mignot E, Ripley B, Nishino S, Earley CJ. Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome. Neurology. 2002;59(4):639\u201341.","journal-title":"Neurology"},{"issue":"10","key":"1055_CR18","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1212\/01.WNL.0000094196.50155.38","volume":"61","author":"K Stiasny-Kolster","year":"2003","unstructured":"Stiasny-Kolster K, Mignot E, Ling L, Moller JC, Cassel W, Oertel WH. CSF hypocretin-1 levels in restless legs syndrome. Neurology. 2003;61(10):1426\u20139.","journal-title":"Neurology"},{"issue":"1","key":"1055_CR19","first-page":"68","volume":"52","author":"AA Berger","year":"2022","unstructured":"Berger AA, Sottosanti ER, Winnick A, Keefe J, Gilbert E, Hasoon J, Thase ME, Kaye AD, Viswanath O, Urits I. Suvorexant in the treatment of difficulty falling and staying asleep (insomnia). Psychopharmacol Bull. 2022;52(1):68\u201390.","journal-title":"Psychopharmacol Bull"},{"issue":"2","key":"1055_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1389-9457(02)00258-7","volume":"4","author":"AS Walters","year":"2003","unstructured":"Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, Trenkwalder C. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003;4(2):121\u201332.","journal-title":"Sleep Med"},{"key":"1055_CR21","unstructured":"W. Guy, National Institute of Mental Health (U.S.). Psychopharmacology Research Branch., Early Clinical Drug Evaluation Program., ECDEU assessment manual for psychopharmacology, Rev. ed., U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD, 1976."},{"key":"1055_CR22","first-page":"235","volume-title":"Measuring functioning and well-being: the medical outcomes study approach","author":"RD Hays","year":"1992","unstructured":"Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE, editors. Measuring functioning and well-being: the medical outcomes study approach. Durham: Duke University Press; 1992. p. 235\u201359."},{"key":"1055_CR23","first-page":"235","volume-title":"Measuring functioning and well-being: the medical outcomes study approach","author":"RD Hays","year":"1992","unstructured":"Hays RD, Stewart AL. Sleep measures. In: Ware JE, editor. Measuring functioning and well-being: the medical outcomes study approach. Durham: Duke University Press; 1992. p. 235\u201359."},{"issue":"7","key":"1055_CR24","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.5665\/sleep.2820","volume":"36","author":"D Garcia-Borreguero","year":"2013","unstructured":"Garcia-Borreguero D, Kohnen R, Boothby L, Tzonova D, Larrosa O, Dunkl E. Validation of the multiple suggested immobilization test: a test for the assessment of severity of restless legs syndrome (Willis\u2013Ekbom disease). Sleep. 2013;36(7):1101\u20139.","journal-title":"Sleep"},{"key":"1055_CR25","unstructured":"American Academy of Sleep Medicine. AASM manual for the scoring of sleep and associated events v2.6, 2020."},{"issue":"10","key":"1055_CR26","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1212\/WNL.59.10.1573","volume":"59","author":"D Garcia-Borreguero","year":"2002","unstructured":"Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology. 2002;59(10):1573\u20139.","journal-title":"Neurology"},{"issue":"4","key":"1055_CR27","doi-asserted-by":"publisher","first-page":"635","DOI":"10.5665\/sleep.3558","volume":"37","author":"D Garcia-Borreguero","year":"2014","unstructured":"Garcia-Borreguero D, Patrick J, DuBrava S, Becker PM, Lankford A, Chen C, Miceli J, Knapp L, Allen RP. Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome. Sleep. 2014;37(4):635\u201343.","journal-title":"Sleep"},{"issue":"23","key":"1055_CR28","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1212\/WNL.0b013e31827688ee","volume":"79","author":"WJ Herring","year":"2012","unstructured":"Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, Lines C, Roth T, Michelson D. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79(23):2265\u201374.","journal-title":"Neurology"},{"key":"1055_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.sleep.2018.11.025","volume":"55","author":"D Garcia-Borreguero","year":"2019","unstructured":"Garcia-Borreguero D, Cano-Pumarega I, Garcia Malo C, Cruz Velarde JA, Granizo JJ, Wanner V. Reduced response to gabapentin enacarbil in restless legs syndrome following long-term dopaminergic treatment. Sleep Med. 2019;55:74\u201380.","journal-title":"Sleep Med"},{"issue":"Pt 4","key":"1055_CR30","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1093\/brain\/awm244","volume":"131","author":"S Fulda","year":"2008","unstructured":"Fulda S, Wetter TC. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies. Brain. 2008;131(Pt 4):902\u201317.","journal-title":"Brain"},{"issue":"3","key":"1055_CR31","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00429-021-02449-8","volume":"227","author":"I Kallo","year":"2022","unstructured":"Kallo I, Omrani A, Meye FJ, de Jong H, Liposits Z, Adan RAH. Characterization of orexin input to dopamine neurons of the ventral tegmental area projecting to the medial prefrontal cortex and shell of nucleus accumbens. Brain Struct Funct. 2022;227(3):1083\u201398.","journal-title":"Brain Struct Funct"},{"issue":"3","key":"1055_CR32","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/ejn.15593","volume":"55","author":"H Kawashima","year":"2022","unstructured":"Kawashima H, Aono Y, Watanabe Y, Waddington JL, Saigusa T. In vivo microdialysis reveals that blockade of accumbal orexin OX(2) but not OX(1) receptors enhances dopamine efflux in the nucleus accumbens of freely moving rats. Eur J Neurosci. 2022;55(3):733\u201345.","journal-title":"Eur J Neurosci"},{"issue":"12","key":"1055_CR33","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1007\/s00213-020-05651-4","volume":"237","author":"JL Haight","year":"2020","unstructured":"Haight JL, Campus P, Maria-Rios CE, Johnson AM, Klumpner MS, Kuhn BN, Covelo IR, Morrow JD, Flagel SB. The lateral hypothalamus and orexinergic transmission in the paraventricular thalamus promote the attribution of incentive salience to reward-associated cues. Psychopharmacology. 2020;237(12):3741\u201358.","journal-title":"Psychopharmacology"},{"issue":"4","key":"1055_CR34","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3344\/kjp.2022.35.4.433","volume":"35","author":"DH Youn","year":"2022","unstructured":"Youn DH, Jun J, Kim TW, Park K. Spinal orexin A attenuates opioid-induced mechanical hypersensitivity in the rat. Korean J Pain. 2022;35(4):433\u20139.","journal-title":"Korean J Pain"},{"issue":"1","key":"1055_CR35","doi-asserted-by":"publisher","first-page":"9224","DOI":"10.1038\/s41598-021-88359-5","volume":"11","author":"Y Higa","year":"2021","unstructured":"Higa Y, Kashiwadani H, Sugimura M, Kuwaki T. Orexinergic descending inhibitory pathway mediates linalool odor-induced analgesia in mice. Sci Rep. 2021;11(1):9224.","journal-title":"Sci Rep"},{"key":"1055_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2022.110639","volume":"120","author":"K Askari","year":"2023","unstructured":"Askari K, Oryan S, Eidi A, Zaringhalam J, Haghparast A. Blockade of the orexin receptors in the ventral tegmental area could attenuate the stress-induced analgesia: a behavioral and molecular study. Prog Neuropsychopharmacol Biol Psychiatry. 2023;120: 110639.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"1055_CR37","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1038\/s41598-020-60518-0","volume":"10","author":"A Ghule","year":"2020","unstructured":"Ghule A, Racz I, Bilkei-Gorzo A, Leidmaa E, Sieburg M, Zimmer A. Modulation of feeding behavior and metabolism by dynorphin. Sci Rep. 2020;10(1):3821.","journal-title":"Sci Rep"},{"key":"1055_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2022.102291","volume":"96","author":"P Shakerinava","year":"2022","unstructured":"Shakerinava P, Sayarnezhad A, Karimi-Haghighi S, Mesgar S, Haghparast A. Antagonism of the orexin receptors in the ventral tegmental area diminished the stress-induced analgesia in persistent inflammatory pain. Neuropeptides. 2022;96: 102291.","journal-title":"Neuropeptides"},{"key":"1055_CR39","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.neuroscience.2022.04.006","volume":"491","author":"V Linehan","year":"2022","unstructured":"Linehan V, Hirasawa M. Short-term fasting induces alternate activation of orexin and melanin-concentrating hormone neurons in rats. Neuroscience. 2022;491:156\u201365.","journal-title":"Neuroscience"},{"issue":"6","key":"1055_CR40","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acn3.51056","volume":"7","author":"L Barateau","year":"2020","unstructured":"Barateau L, Chenini S, Lotierzo M, Rassu AL, Evangelista E, Lopez R, Gorce Dupuy AM, Jaussent I, Dauvilliers Y. CSF and serum ferritin levels in narcolepsy type 1 comorbid with restless legs syndrome. Ann Clin Transl Neurol. 2020;7(6):924\u201331.","journal-title":"Ann Clin Transl Neurol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01055-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-01055-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01055-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T17:50:43Z","timestamp":1706205043000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-01055-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1055"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-01055-y","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"15 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was supported by an unrestricted research grant from MSD Ltd to Diego Garcia-Borreguero.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Garcia-Borreguero has received research grants from MSD and Roche and consultancy fees from Idorsia. Drs. Garcia Arag\u00f3n, Moncada, Romero, Granizo, Quintas, and Castillo report no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data generated during the course of this study are available upon reasonable request. The study protocol can be viewed by contacting the corresponding author. No changes were made to the methods, including outcomes, after trial commencement.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"The study was performed at the Sleep Research Institute, in Madrid, Spain, and approved by the local institutional review board (CEIC Hospital La Princesa, Madrid) on Dec 23, 2017 (approval number: 21\/2017).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"DGB conceived and designed the analysis; DGB, AG, BM, and SR collected and analyzed the data. Statistical analysis completed by JJG. All authors contributed to the analysis of data and the writing of the paper, approved the current manuscript, and accepted its submission to CNS Drugs.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Written informed consent was obtained from all participants.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}